ライフサイエンスコーパス: pulmonary function test

1 al interstitial pneumonia than an individual pulmonary function test.

2 r-mo/cc cumulative exposure prior to initial pulmonary function test.

3 rs and accumulated RCF exposure from initial pulmonary function test.

4 Background: Spirometry is the most common pulmonary function test.

5 -Pick disease was evaluated with imaging and pulmonary function tests.

6 who had significantly abnormal pretransplant pulmonary function tests.

7 , echocardiogram, treadmill stress test, and pulmonary function tests.

8 aded exercise testing, echocardiography, and pulmonary function tests.

9 h LAM (17 with pleurodesis) underwent CT and pulmonary function tests.

10 able from traditional imaging modalities and pulmonary function tests.

11 d by symptom activity than medication use or pulmonary function tests.

12 luded in the analysis provided at least five pulmonary function tests.

13 ry symptom questionnaire; 736 also performed pulmonary function tests.

14 gnant smokers significantly improved newborn pulmonary function tests.

15 s from a 15-item questionnaire and completed pulmonary function tests.

16 Scale, grip strength, 5-meter walk test, and pulmonary function tests.

17 m review, high-resolution CT evaluation, and pulmonary function tests.

18 l pulmonary vessel volume is associated with pulmonary function tests.

19 s these results in a new cohort using infant pulmonary function tests.

20 radiomics data was compared to conventional pulmonary function tests.

21 need for a standardized reporting format for pulmonary function tests.

22 ual scores and clinical parameters including pulmonary function tests.

23 ndings are more sensitive as compared to the pulmonary function tests.

24 ar retinal nerve fiber layer correlates with pulmonary function tests.

25 standardized interview, skin prick tests and pulmonary function tests.

26 hickness, and body composition), asthma, and pulmonary function tests.

27 ee survival, modified Rodnan skin score, and pulmonary function tests.

28 ved in kidney angiomyolipoma size but not in pulmonary function tests.

29 nts were prospectively followed with routine pulmonary function tests.

30 A diagnosis of asthma was confirmed by pulmonary function testing.

31 ed diffusion capacity for carbon monoxide on pulmonary function testing.

32 ion, and the following day were subjected to pulmonary function testing.

33 in a group of patients who were referred for pulmonary function testing.

34 Day 1 consisted of anthropometry and pulmonary function testing.

35 y system mechanical properties complementing pulmonary function testing.

36 the patients were correlated with results of pulmonary function testing.

37 chest radiographs (489 patients [8.2%]) and pulmonary function tests (127 patients [3.4%]).

38 nonobstructive pattern (FEV(1):VC >/=0.7) in pulmonary function tests 3 months after transplantation.

39 reated outside the ICU) were evaluated using pulmonary function testing, 6-minute-walk test, echocard

40 lassifications were associated with impaired pulmonary function tests, 6-minute walk distance, and St

41 sometimes in individuals without symptoms or pulmonary function test abnormalities.

42 The CPI was derived in group I (by fitting pulmonary function tests against disease extent on CT) a

43 included individual arm and leg megascores, pulmonary function tests, an activities-of-daily-living

44 patients with SSc should undergo a baseline pulmonary function test and lung HRCT screening to diagn

45 completed a clinical assessment, followed by pulmonary function testing and a 6MST.

46 comitant symptoms, the physical examination, pulmonary function testing and arterial blood gas analys

47 th SSc and dyspnea were evaluated for ILD by pulmonary function testing and bronchoalveolar lavage (B

48 pational asbestos exposure who had undergone pulmonary function testing and computed tomographic (CT)

49 nt (HDC/ABMT) for primary breast cancer with pulmonary function testing and computed tomography at re

50 mmendations addressing the role of screening pulmonary function testing and diagnostic tests in child

51 ysis of variance, and the relationships with pulmonary function testing and eosinophil counts were as

52 dditional research about the roles of infant pulmonary function testing and food avoidance or dietary

53 To review the recent literature related to pulmonary function testing and how it relates to the pre

54 Both in vivo pulmonary function testing and lung histopathology scori

55 CT scores were then compared with results of pulmonary function testing and patient age by means of l

56 univariable and multivariable analyses with pulmonary function testing and quality of life survey da

57 Other pulmonary function tests and arterial blood gas measurem

58 Pulmonary function tests and Brasfield scores were withi

59 ho had undergone pre- and postbronchodilator pulmonary function tests and computed tomographic (CT) e

60 macular sub-layer thickness measurements and pulmonary function tests and disease duration.

61 ese, 219 patients were able to complete both pulmonary function tests and Dlco measurement.

62 mographic and clinical parameters, including pulmonary function tests and high resolution computed to

63 Metabolic stress testing (VO(2)), pulmonary function tests and isokinetic strength testing

64 Results of pulmonary function tests and other measures of major org

65 postoperative pulmonary complications, while pulmonary function tests and the assessed indicators of

66 Relationships between findings at CT and pulmonary function tests and the influence of pleurodesi

67 Pulmonary function tests and time since symptom onset we

68 m the diaphragms of two patients with normal pulmonary function tests and two patients with severe CO

69 COPD is assessed by pulmonary-function tests and computed tomography-based a

70 ictive lung pattern revealed by preoperative pulmonary function tests) and the transfusion (blood uni

71 physician, 23.4% (13.9-36.6) had a previous pulmonary function test, and 5.6% (3.1-9.9) had been tre

72 cil sum score and handgrip strength), a full pulmonary function test, and a chest CT scan which was u

73 .5 (range, 21.0-67.8) years at time of first pulmonary function test, and a median follow-up of 5.5 y

74 pneumonia, fixed obstructive lung disease on pulmonary function testing, and characteristic changes o

75 tom scores, arterial blood gas measurements, pulmonary function testing, and chest radiographs.

76 STL-1 Hypo) mice underwent lung morphometry, pulmonary function testing, and micro-computed tomograph

77 icipants underwent chest CT, HP (129)Xe MRI, pulmonary function testing, and the 1-minute sit-to-stan

78 tric measurements, resting echocardiography, pulmonary function tests, and a cardiopulmonary exercise

79 All patients underwent pulmonary function tests, and measurement of fraction of

80 nally for 3 years, and demographics, stages, pulmonary function tests, and organ involvements were re

81 ic resonance imaging (MRI), echocardiograms, pulmonary function tests, and physical examinations.

82 l infiltrates, gas exchange abnormalities on pulmonary function tests, and pleural thickening on ches

83 ions between [(18)F]FDG PET/CT measurements, pulmonary function tests, and the established model base

84 and exposure history, physical examination, pulmonary-function testing, and high-resolution computed

85 Objectives: To assess physical examination, pulmonary function tests, anxiety, depression, post-trau

86 bar weakness, and paradoxical breathing) and pulmonary function testing are ideal for risk stratifica

87 Background Pulmonary function tests are central to diagnosis and mo

88 >/=10% decline in FEV1 relative to the prior pulmonary function test, are subsequently at increased r

89 ic fibrosis pulmonary disease is assessed by pulmonary function tests, arterial blood gases, and ches

90 Response was monitored by chest radiographs, pulmonary function tests, arterial blood gases, and grad

91 Measurements: Polysomnography, pulmonary function tests, arterial blood gases, and left

92 ized organisms does not occur during routine pulmonary function testing as long as an interval of 5 m

93 Pulmonary function tests, Asthma Control Test (ACT), Ast

94 rticosteroids, use of inhaled beta-agonists, pulmonary function tests, asthma symptom assessment, and

95 ell Disease, was constructed using the first pulmonary function test at >21 years of age.

96 Pulmonary function testing at 3 mo after lung transplant

97 nts from 12 trial centers were recruited for pulmonary function testing at a single center.

98 They also underwent pulmonary function testing at baseline CT and at 5 years

99 Among survivors with normal pulmonary function tests at t1, females and survivors tr

100 ated more strongly (rho = 0.75, P <.01) with pulmonary function test-based scores than did inspirator

101 n by graft bronchoalveolar lavage cells, and pulmonary function testing before and during cyclosporin

102 ing or not having airflow limitation through pulmonary function tests before and after the use of a b

103 nt Gal-3 assessment using plasma samples and pulmonary function testing between 1995 and 1998.

104 bjects and 30 patients with asthma underwent pulmonary function tests, blood and sputum eosinophil co

105 ollowed and outcome measures included serial pulmonary function tests, blood gases, lung compliance,

106 We analyzed pulmonary function tests, blood, and bronchoscopic biops

107 CT before and after surgery, with concurrent pulmonary function testing, body mass index calculation,

108 Pulmonary function tests, Brasfield scores, arterial blo

109 high-resolution computed tomography, infant pulmonary function testing, bronchoscopy with bronchoalv

110 thy lungs and are related to measurements of pulmonary function testing but not to eosinophil level.

111 ant linear correlations with measurements of pulmonary function testing but not with eosinophil level

112 t clinical improvement with normalization of pulmonary function tests by 1 year posttransplant.

113 ompared with baseline CT fibrosis scores and pulmonary function tests by using Spearman rank correlat

114 Pulmonary function testing can be used to quantify lung

115 e lymphatic edema, marked improvement in his pulmonary function tests, cessation of supplemental oxyg

116 t included the completion of questionnaires, pulmonary function testing, chest computed tomography, a

117 , serum ferritin (iron overload, 24.0%), and pulmonary function testing/chest x-ray (pulmonary dysfun

118 Each subject underwent pulmonary function testing, completed a detailed questio

119 Participants underwent pulmonary function testing, CT, and MRI.

120 d by the combination of imaging findings and pulmonary function testing decrements).

121 tricular tachycardia episodes (p=0.025), and pulmonary function testing demonstrated improved forced

122 extent on CT (r2 = 0.51) than the individual pulmonary function test (DLCO the highest value, r2 = 0.

123 clinical history and examination, CD4 count, pulmonary function tests, Doppler echocardiography, and

124 onventional clinical measurements, including pulmonary function tests, during a period of disease sta

125 xamination that included carotid ultrasound, pulmonary function tests, ECG, and echocardiography.

126 ounds should be considered when interpreting pulmonary function tests, especially when predicted valu

127 ubjects underwent sputum and blood analyses, pulmonary function testing, exercise tolerance, and qual

128 .20 +/- 0.17, FEV1/FVC 40 +/- 3) we measured pulmonary function tests, exercise breathlessness by Bor

129 as performed using questionnaires, atopy and pulmonary function testing, exhaled nitric oxide measure

130 administered before and after exposure, and pulmonary function tests (FEV1, FVC, and specific airway

131 administered before and after exposure, and pulmonary function tests (FEV1, FVC, and SRaw) were perf

132 L enhanced the prognostic utility of pre-HCT pulmonary function tests for the outcome of post-HCT mor

133 ased inspiratory flows at rest measured with pulmonary function tests (forced inspiratory volume in o

134 ent's global assessment of disease activity, pulmonary function tests (forced vital capacity, diffusi

135 rs examined cross-sectional dietary data and pulmonary function tests from 2,566 children aged 11-19

136 Pulmonary function tests, gas exchange, 6-min walk dista

137 All pulmonary function tests had returned to baseline values

138 Postoperative pulmonary function testing has shown significant improve

139 rocardiograms (EKGs), chest radiographs, and pulmonary function tests have been obtained from each pa

140 ective standardized evaluation included full pulmonary function testing, high-resolution chest tomogr

141 Symptomatic employees had chest radiography, pulmonary function tests, high-resolution computed tomog

142 (F1), moderate (F2), or severe (F3) based on pulmonary function tests, high-resolution CT, and clinic

143 e range, 10-37 years) successfully underwent pulmonary function tests, hyperpolarized (3)He MRI, and

144 e Physician Global Assessment and muscle and pulmonary function tests improved, and there were no det

145 edicted more accurately by the CPI than by a pulmonary function test in all clinical subgroups, inclu

146 -deleted donor T cells did not have improved pulmonary function tests in contrast with the markedly i

147 ays directly, but unfortunately conventional pulmonary function tests in human subjects are not speci

148 Pulmonary function tests in infants have been used for m

149 The three methods and the pulmonary function tests in the normal and emphysema gro

150 Baseline pulmonary function tests included spirometry before and

151 Pulmonary function tests, including diffusing capacity o

152 Pulmonary function tests, including lung volumes, arteri

153 tion computed tomography (HRCT) patterns and pulmonary function tests, including the composite physio

154 Although pulmonary function test indexes may be abnormal, imaging

155 7) and healthy controls (CON, n = 7) during pulmonary function tests, inspiratory endurance testing,

156 were evaluated with a symptom questionnaire, pulmonary function testing, intradermal allergen testing

157 t forced expiratory flows and volumes infant pulmonary function tests (iPFTs) were measured in 44 inf

158 An obstructive pattern in pulmonary function test is common after lung transplanta

159 , the quantitation of disease severity using pulmonary function tests is often confounded by emphysem

160 , with expertise in conducting and analyzing pulmonary function tests, laboratory quality assurance,

161 alue where reference-standard tools, such as pulmonary function tests, lack sensitivity.

162 ological and neuropsychological assessments, pulmonary function tests, liver and spleen organ volumes

163 Exertional dyspnea disproportionate to pulmonary function tests, low carbon monoxide diffusion

164 On pulmonary function testing, LPS-treated mice had increas

165 he ambulatory care visit, patients underwent pulmonary function tests, lung computed tomographic scan

166 Pulmonary function tests, markers of atopy, asthma diagn

167 Correlations between mean ADC values and pulmonary function test measurements for diagnosing emph

168 Longitudinal changes in DW MRI and pulmonary function test measurements were assessed with

169 and, according to their symptoms, underwent pulmonary function testing, methacholine challenge, spec

170 e data, radiologic imaging, and non-invasive pulmonary function testing (MGC Diagnostic Platinum Elit

171 mes included abnormalities determined by the pulmonary function tests of forced vital capacity (FVC)

172 ing questionnaires or office-based screening pulmonary function testing or to determine the benefits

173 at least 25 percent in exercise tolerance or pulmonary-function tests or resolution or absence of pul

174 f inhaled corticosteroids were predictive of pulmonary function tests' outcome.

175 r than 18 yr of age and performed at least 3 pulmonary function tests over 5 to 20 yr.

176 During an asthma exacerbation, pulmonary function test parameters (PFTs) return to thei

177 Infant pulmonary function testing performed as an exploratory o

178 Study participants had pulmonary function testing performed at regular preset i

179 r lavage (BAL) metatranscriptomes and paired pulmonary function tests performed a median of 1 to 2 we

180 Pulmonary function test (PFT) impairments were present i

181 d ethnicity-specific reference equations for pulmonary function test (PFT) interpretation.

182 e and ethnicity are routinely used to inform pulmonary function test (PFT) interpretation.

183 All patients had normal biopsy and stable pulmonary function test (PFT) results 2-36 weeks prior t

184 ere assessed by using chest radiographic and pulmonary function test (PFT) results in 93 patients.

185 tomography (CT) metrics on a lobar basis and pulmonary function test (PFT) results on a whole-lung ba

186 sing spondylitis (AS) and compared them with pulmonary function test (PFT) results, demographic chara

187 ctive pulmonary disease (COPD), based on the pulmonary function test (PFT), to correlate the various

188 Pulmonary function testing (PFT) allows for quantitative

189 Pulmonary function testing (PFT) is an important compone

190 f asthma and/or EIB were required to undergo pulmonary function testing (PFT) to permit the use of in

191 Serial pulmonary function testing (PFT) was performed.

192 Respiratory muscle function was assessed by pulmonary function testing (PFT).

193 We performed pulmonary function tests (PFT), measured slope of phase

194 duration of illness, laboratory results and pulmonary function tests (PFT).

195 Pulmonary function tests (PFTs) and symptom evaluation w

196 cystic fibrosis (CF), recurrent imaging and pulmonary function tests (PFTs) are needed for the asses

197 Pulmonary function tests (PFTs) are routinely used to as

198 magnetic resonance imaging ((129)Xe MRI) and pulmonary function tests (PFTs) are sensitive to lung fu

199 Pulmonary function tests (PFTs) assessed forced expirato

200 rological profiles were assessed by HRCT and pulmonary function tests (PFTs) at baseline (Year 0) and

201 erogeneity is greater in smokers with normal pulmonary function tests (PFTs) but who have visual evid

202 Besides the global pulmonary function tests (PFTs) imaging techniques gaine

203 We sought to perform objective pulmonary function tests (PFTs) in HIV-infected and HEU

204 Pulmonary function tests (PFTs) included forced vital ca

205 Removal of race correction in pulmonary function tests (PFTs) is a priority, given tha

206 unenhanced supine CT scans of the chest and pulmonary function tests (PFTs) performed within 3 month

207 Pulmonary function tests (PFTs) that measured the diffus

208 earning algorithm and that obtained by using pulmonary function tests (PFTs) was then evaluated in th

209 After the stabilization period, pulmonary function tests (PFTs) were measured (period 1)

210 Pulmonary function tests (PFTs) were performed before in

211 d to assess the correlation of CT scores and pulmonary function tests (PFTs) with this clinical outco

212 33 UW and 57 NW patients and compared their pulmonary function tests (PFTs), arterial blood gases (A

213 Unfortunately many of them, for example pulmonary function tests (PFTs), clinical signs and conv

214 ging session followed by clinically standard pulmonary function tests (PFTs), the 6-minute walk test,

215 cluded time to death or worsening results of pulmonary function tests (PFTs).

216 mptom-limited incremental cycle exercise and pulmonary functions tests (PFTs) and were compared with

217 h SA and its specific characteristics (i.e., pulmonary function tests, quality of life scores, urgent

218 o adverse events led to discontinuation, and pulmonary function tests remained stable.

219 After 8 wk of pulmonary rehabilitation, pulmonary function tests remained unchanged compared wit

220 went history, physical examination, complete pulmonary function testing, respiratory muscle testing,

221 ge, sex, height, weight, body index mass, or pulmonary function test results and each lung attenuatio

222 erapy for symptomatic patients with abnormal pulmonary function test results and lung infiltrates.

223 Changes reported in analysis of pulmonary function test results and their follow-up migh

224 survey and had reliable post-bronchodilator pulmonary function test results and were thus included i

225 available in the United States; if baseline pulmonary function test results are normal to near norma

226 Pulmonary function test results before and after ARS rev

227 omputed tomography (HRCT) chest scans and/or pulmonary function test results in patients with CVID an

228 Pulmonary function test results showed correlations with

229 relation between CT finding extent score and pulmonary function test results was estimated with Spear

230 Pulmonary function test results were as follows: forced

231 Age and pulmonary function test results were similar in RA and n

232 ge (BAL) cell components, chest radiography, pulmonary function test results, and exercise physiology

233 A review of clinical records, pulmonary function test results, and findings on imaging

234 reatment and posttreatment HRCT scan scores, pulmonary function test results, and lymphocyte subsets

235 be tapered over 6 to 18 months if symptoms, pulmonary function test results, and radiographs improve

236 On the basis of clinical information and pulmonary function test results, disease in 53 patients

237 Of the 15 control patients with normal pulmonary function test results, six (40%) had mosaic pe

238 the relationship between CT measurements and pulmonary function test results.

239 True diagnosis was based on pulmonary function test results.

240 f air trapping correlated significantly with pulmonary function test results.

241 have CT abnormalities than those with normal pulmonary function test results.

242 g Final diagnoses in all patients were based pulmonary function test results.

243 nd have parenchymal infiltrates and abnormal pulmonary function test results.

244 s and participant characteristics, including pulmonary function test results.

245 malignancy, and had available pretransplant pulmonary function test results.

246 evelop a new Technical Standard on reporting pulmonary function test results.

247 est, exercise), PaO2, hemoglobin, or resting pulmonary function test results.

248 c (HLA class II and FBN1 genotypes) factors; pulmonary function test results; electrocardiograms; and

249 Pulmonary function testing revealed no significant diffe

250 Pulmonary function testing revealed severe airflow limit

251 Both pre- and postexercise pulmonary function tests revealed air trapping and mild

252 In addition, pulmonary function tests revealed stable vital capacity

253 Pulmonary function testing reveals an obstructive ventil

254 atients evaluated with standard preoperative pulmonary function tests, RV/TLC again was found to corr

255 volume was reproducible and correlated with pulmonary function testing severity, and it improved aft

256 Pulmonary function testing showed that O(3)-induced redu

257 Pulmonary function tests showed low Dl(CO) (30% [12-79%]

258 Emphysema along the needle path, pulmonary function tests showing ventilatory obstruction

259 s on chest radiographs (ten [67%] of 15) and pulmonary function tests (six [67%] of nine).

260 Preoperative objective variables (pulmonary function tests, smoking history, demographics,

261 ction (by impedance plethysmography), serial pulmonary function tests (spirometry and diffusion capac

262 Health Toolbox Cognition Battery (NIHTB-CB), pulmonary function tests (spirometry, diffusion capacity

263 e and is variably correlated with results of pulmonary function tests, suggesting that the SF-36 shou

264 When performing infant pulmonary function testing, TAC itself produces a tempor

265 were delivered by C-section and subjected to pulmonary function testing the following day.

266 Participants with CF also underwent pulmonary function tests the same day.

267 ment of lung, cardiac, and sleep function by pulmonary function tests, transthoracic echocardiography

268 mixed-effects model showed that the slope of pulmonary function tests values, including percent vital

269 2.2 to 5.6]) and a mild decrease in certain pulmonary function testing variables, which did not prog

270 A pulmonary function test was performed measuring prebronc

271 Pulmonary function testing was done and in-person interv

272 An obstructive pattern on pulmonary function testing was observed in 57.3% of the

273 Pulmonary function testing was performed according to gu

274 Pulmonary function testing was performed, including forc

275 Pulmonary function tests were (%predicted): FEV(1) = 27%

276 Pulmonary function tests were almost normal at 6 months,

277 Pulmonary function tests were also performed.

278 ce of lesion from the pleura, and results of pulmonary function tests were analyzed as single and mul

279 Pulmonary function tests were assessed at baseline (n =

280 Pulmonary function tests were completed on 3,293 subject

281 Pulmonary function tests were done at baseline and at th

282 Serial pulmonary function tests were done.

283 The results of the pulmonary function tests were expressed as the percentag

284 Pulmonary function tests were obtained immediately befor

285 ent a comprehensive clinical assessment, and pulmonary function tests were obtained.

286 tion and expiration, visual HRCT scores, and pulmonary function tests were obtained.

287 Bronchoalveolar lavage and pulmonary function tests were performed at intervals.

288 -terminal pro-brain natriuretic peptide, and pulmonary function tests were performed before (baseline

289 raphy, conventional and thin-section CT, and pulmonary function tests were performed in 39 patients.

290 Serial echocardiograms and pulmonary function tests were performed.

291 functional tests, functional parameters, and pulmonary function tests were secondary outcome measures

292 Pulmonary function tests were similarly obtained before

293 Pulmonary function tests were stable in 22 of the 26 pat

294 Data on cardiopulmonary-exercise and pulmonary-function testing were compared with data obtai

295 ions, computed tomography of lung cysts, and pulmonary-function tests were performed.

296 Pulmonary function test with a flow-volume loop curve sh

297 plete blood count, and serum chemistries and pulmonary function testing with bronchoprovocation in se

298 iagnosing BOS in patients with first drop of pulmonary function tests with a sensitivity of 96% and a

299 Chest X-ray film and pulmonary function tests with diffuse capacity of carbon

300 Pulmonary function tests, X-rays, computed tomographic (